Novel Genotoxic Impurities in the First‐Line Oral Anticoagulant Drug, Apixaban: Computational Toxicological Evaluation and Development of a Highly Sensitive LC‐MS/MS Quantification Method
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Bhaskar Vallamkonda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Science, School of Applied Sciences and Humanities, Vignan's Foundation for Science, Technology & Research, Guntur, Andh…. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Pyridones, Pyrazoles, Drug Contamination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Apixaban is an oral anticoagulant classified as a direct factor Xa inhibitor. It is widely utilized for prophylaxis and management of thromboembolic conditions, including stroke, deep vein thrombosis, and pulmonary embolism, as a primary therapeutic option. Apixaban is subjected to stringent testing for potential genotoxic impurities during its manufacturing, due to its structure indicating the possibility of such impurity's formation. Setting limits in accordance with ICH M7 guidelines is essential to reduce patient exposure and also recommended an advanced analytical tool for testing. The present study aims to establish limits based on computational toxicological evaluation, and develop and validate a highly sensitive LS‐MS/MS method for quantifying three novel genotoxic impurities of apixaban, namely impurities F, G, and H. The method was established utilizing a mobile phase comprising a pH 5.5 acetate buffer and acetonitrile in a gradient mode. Used a C18 column, of 150 mm (length) × 3.0 mm (width), 2.7 μm of particle size as stationary phase. Quantification was performed with multi‐response monitoring in mass spectrometry, employing precursor ions of m/z 437.2, 525.2, and 569.1 for impurities F, G, and H, respectively. The established method is validated for its intended use in accordance with regulatory guidelines and found suitable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Science, School of Applied Sciences and Humanities, Vignan's Foundation for Science, Technology & Research, Guntur, Andhra Pradesh, India.
- Department of Pharmaceutical Analysis, Vignan Institute of Pharmaceutical Technology, Visakhapatnam, Andhra Pradesh, India.
ORCID-Profile: Bhaskar Vallamkonda, Srinivasa Rao Yarguntla, Ranadheer Reddy Challa
Zitieren
APA
Vallamkonda, B., Yarguntla, S. R., & Challa, R. R. (2025). Novel Genotoxic Impurities in the First‐Line Oral Anticoagulant Drug, Apixaban: Computational Toxicological Evaluation and Development of a Highly Sensitive LC‐MS/MS Quantification Method. Biomedical Chromatography. https://doi.org/10.1002/bmc.70043
Vancouver
Vallamkonda B, Yarguntla SR, Challa RR. Novel Genotoxic Impurities in the First‐Line Oral Anticoagulant Drug, Apixaban: Computational Toxicological Evaluation and Development of a Highly Sensitive LC‐MS/MS Quantification Method. Biomedical Chromatography. 2025. doi:10.1002/bmc.70043
BibTeX
@article{Vallamkonda2025,
author = {Vallamkonda, Bhaskar and Yarguntla, Srinivasa Rao and Challa, Ranadheer Reddy},
title = {Novel Genotoxic Impurities in the First‐Line Oral Anticoagulant Drug, Apixaban: Computational Toxicological Evaluation and Development of a Highly Sensitive LC‐MS/MS Quantification Method},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70043}
}
EUVIMED